Posted inBiotechnology
Surrogate Models Help Engineers Squeeze More Performance From Rocket Thrust Chambers
The thrust chamber is the beating heart of any liquid-propellant rocket engine, the place where fuel and oxidizer meet, burn…
Posted inGenetics
Advancing AAV Development: From Production to Performance
Thomas Quinn R&D Group LeaderTakara Bio USA Panelist Thomas Quinn Thomas Quinn earned a BS in zoology (genetics) from Michigan…
Posted inBiotechnology
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened…
Posted inGenetics
Best Practices for Establishing Data Integrity in Western Blotting
Western blotting, a lab method used to detect specific proteins. [Nilrat Wannasilp/Getty Images] Western blotting is a fundamental technique, supporting…
Posted inBiotechnology
Novartis secures new radioligand in $900M deal as competition strengthens
As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a…
Posted inBiotechnology
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
Posted inBiotechnology
Amgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 win
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive…
Posted inBiotechnology
Vertex’s midstage data amplify kidney disease market opportunity
Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the…
Posted inBiotechnology
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich…
Posted inBiotechnology
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning…